for males ages 18 years and up (full criteria)
at San Francisco, California
study started
estimated completion
Thomas Hope



The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.

Official Title

Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence


Prostate Cancer Recurrence Edetic Acid Ga-68 labeled PSMA-11 PET


You can join if…

Open to males ages 18 years and up

  • Histopathologically proven prostate adenocarcinoma.
  • Rising prostate-specific antigen (PSA) (at least two consecutive rising PSAs) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).
  • Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation for biochemical recurrence after radical prostatectomy
  • PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.
  • Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical recurrence after radiation therapy
  • Nadir + greater than or equal to 2 ng/mL rise in PSA
  • Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).
  • Age >= 18.
  • Ability to understand a written informed consent document, and the willingness to sign it.

You CAN'T join if...

  • Unable to lie flat, still or tolerate a PET scan.
  • Concomitant investigational therapy.
  • Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
  • Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device).


  • University of California, San Francisco
    San Francisco California 94143 United States

Lead Scientist


in progress, not accepting new patients
Start Date
Completion Date
Thomas Hope
Phase 3
Study Type
Last Updated